José Adélaïde
French Institute of Health and Medical Research
CancerMolecular biologyCancer researchBreast cancerBiology
What is this?
Publications 146
#1José Adélaïde (AMU: Aix-Marseille University)H-Index: 50
#1José Adelaïde (AMU: Aix-Marseille University)H-Index: 1
Last. Véronique Gelsi-Boyer (AMU: Aix-Marseille University)H-Index: 25
view all 9 authors...
#1Lénaïg MescamH-Index: 2
#2Vincent Camus (French Institute of Health and Medical Research)H-Index: 30
Last. Fabrice Jardin (French Institute of Health and Medical Research)H-Index: 31
view all 19 authors...
#1François Bertucci (AMU: Aix-Marseille University)H-Index: 32
#2C RypensH-Index: 2
Last. Steven Van LaereH-Index: 35
view all 20 authors...
Inflammatory breast cancer (IBC) is the most pro-metastatic form of breast cancer. Better understanding of its pathophysiology and identification of actionable genetic alterations (AGAs) are crucial to improve systemic treatment. We aimed to define the DNA profiles of IBC vs noninflammatory breast cancer (non-IBC) clinical samples in terms of copy number alterations (CNAs), mutations, and AGAs. We applied targeted next-generation sequencing (tNGS) and array-comparative genomic hybridization (aCG...
2 CitationsSource
#1Frédéric Courtier (AMU: Aix-Marseille University)H-Index: 2
#2Séverine Garnier (French Institute of Health and Medical Research)H-Index: 1
Last. Anne Murati (French Institute of Health and Medical Research)H-Index: 22
view all 15 authors...
#2Pascal FinettiH-Index: 43
Last. François BertucciH-Index: 52
view all 9 authors...
Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with di...
#1Cecile Vicier (AMU: Aix-Marseille University)H-Index: 2
#2Nicolas IsambertH-Index: 31
Last. Anthony Gonçalves (AMU: Aix-Marseille University)H-Index: 15
view all 16 authors...
1091Background: Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)-pathway is frequently activated in HER2-negative breast cancer and may play a role in taxane-resistance...
1 CitationsSource
#1Brice ChanezH-Index: 2
#2Romain AppayH-Index: 3
Last. Emeline Tabouret (AMU: Aix-Marseille University)H-Index: 12
view all 20 authors...
e13535Background: GB are highly aggressive tumors which systematically relapse. Our objective was to identify disease progression mechanisms and genomic drivers of GB treatment resistance. Methods:...
#1Marguerite TyranH-Index: 2
#2Nadine CarbucciaH-Index: 20
Last. François BertucciH-Index: 52
view all 14 authors...
Improving the systemic treatment of brain metastases (BM) in primary breast cancer (PBC) is impaired by the lack of genomic characterization of BM. To estimate the concordance of DNA copy-number-alterations (CNAs), mutations, and actionable genetic alterations (AGAs) between paired samples, we performed whole-genome array-comparative-genomic-hybridization, and targeted-next-generation-sequencing on 14 clinical PBC–BM pairs. We found more CNAs, more mutations, and higher tumor mutational burden, ...
1 CitationsSource
#1Anne Wanquet (AMU: Aix-Marseille University)H-Index: 4
#2Frédéric Courtier (AMU: Aix-Marseille University)H-Index: 2
Last. Anne Murati (AMU: Aix-Marseille University)H-Index: 2
view all 12 authors...
2 CitationsSource